Related Experiment Video
Updated: Jul 23, 2025

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Published on: January 24, 2016
N6-methyladenosine-modified circIRF2, identified by YTHDF2, suppresses liver fibrosis via facilitating FOXO3 nuclear
Xin Chen1, Sai Zhu2, Hai-Di Li1
1Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-inflammatory and Immune Medicines, Anhui Medical University, Ministry of Education, Hefei 230032, China; Institute for Liver Diseases of Anhui Medical University, ILD-AMU, Anhui Medical University, Hefei 230032, China.
Abstract:
Circular RNA (circRNA) has been implicated in liver fibrosis and modulated by multiple elusive molecular mechanisms, while the effects of N6-methyladenosine (m6A) modification on circRNA are still elusive. Herein, we identify circIRF2 from our circRNA sequencing data, which decreased in liver fibrogenesis stage and restored in resolution stage, indicating that dysregulated circIRF2 may be closely associated with liver fibrosis. Gain/loss-of-function analysis was performed to evaluate the effects of circIRF2 on liver fibrosis at both the fibrogenesis and resolution in vivo. Ectopic expression of circIRF2 attenuated liver fibrogenesis and HSCs activation at the fibrogenesis stage, whereas downregulation of circIRF2 impaired mouse liver injury repair and inflammation resolution. Mechanistically, YTHDF2 recognized m6A-modified circIRF2 and diminished circIRF2 stability, partly accounting for the decreased circIRF2 in liver fibrosis. Microarray was applied to investigate miRNAs regulated by circIRF2, our data elucidate cytoplasmic circIRF2 may directly harbor miR-29b-1-5p and competitively relieve its inhibitory effect on FOXO3, inducing FOXO3 nuclear translocation and accumulation. Clinically, circIRF2 downregulation was prevalent in liver fibrosis patients compared with healthy individuals. In summary, our findings offer a novel insight into m6A modification-mediated regulation of circRNA and suggest that circIRF2 may be an exploitable prognostic marker and/or therapeutic target for liver fibrosis.
Insights
Circular RNA IRF2 (circIRF2) is reduced in liver fibrosis. Restoring circIRF2 alleviates fibrosis by regulating miR-29b-1-5p and FOXO3, suggesting circIRF2 as a therapeutic target.
Area of Science:
- Molecular Biology
- Hepatology
- Epigenetics
Background:
- Circular RNAs (circRNAs) play roles in liver fibrosis through unknown mechanisms.
- N6-methyladenosine (m6A) modification influences gene expression but its role in circRNA regulation in fibrosis is unclear.
Purpose of the Study:
- To investigate the role of circIRF2 in liver fibrosis.
- To elucidate the molecular mechanisms underlying circIRF2 regulation and function in liver fibrosis.
- To assess circIRF2 as a potential biomarker or therapeutic target for liver fibrosis.
Main Methods:
- circRNA sequencing to identify circIRF2.
- In vivo gain/loss-of-function studies in mice to assess circIRF2's role in fibrogenesis and resolution.
- Mechanistic studies involving m6A reader YTHDF2, miRNA-mRNA interactions (miR-29b-1-5p, FOXO3), and protein localization.
- Microarray analysis to identify circIRF2-regulated miRNAs.
- Clinical sample analysis to compare circIRF2 levels in patients with liver fibrosis and healthy individuals.
Main Results:
- circIRF2 levels decreased during liver fibrogenesis and were restored during resolution.
- Ectopic circIRF2 expression attenuated liver fibrosis and hepatic stellate cell (HSC) activation.
- circIRF2 downregulation impaired liver injury repair and inflammation resolution.
- YTHDF2 recognized m6A-modified circIRF2, reducing its stability.
- circIRF2 sponged miR-29b-1-5p, relieving its inhibition on FOXO3 and promoting FOXO3 nuclear translocation.
- circIRF2 downregulation was observed in liver fibrosis patients.
Conclusions:
- circIRF2 is a crucial regulator in liver fibrosis progression and resolution.
- m6A modification and YTHDF2 contribute to decreased circIRF2 stability in liver fibrosis.
- The circIRF2/miR-29b-1-5p/FOXO3 axis is a key pathway in liver fibrosis.
- circIRF2 represents a potential prognostic marker and therapeutic target for liver fibrosis.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Introduction to Fibroblasts

